Discover key insights from BioCentury’s survey on U.S. political developments. Explore industry sentiment, top concerns and download the full report for in-depth analysis.

FDA has missed another PDUFA review deadline, this time for a treatment that a small biotech is developing for an ultrarare disease. Stealth Biotherapeutic...

YouTube video by BioCentury Video

With a new $110 million series B led by Medicxi, Seattle-based Curevo is moving a potential competitor to blockbuster shingles vaccine Shingrix toward...

The rising competition from China is to be welcomed not feared, says John Maraganore, who argues the innovation will push biotechs globally to greater...

Two Houston measles cases have public health officials worried about possible outbreak.

It’s arguable as to whether the chaos around the executive orders this week in which NIH has been swept up is a feature or a bug of the Trump admini...

If anyone still doubts the competitiveness of China biotechs in innovation and dealmaking, the boom of companies founded on the so-called “NewCo Mod...

Guggenheim Securities announced today that Jami Rubin will join the firm’s healthcare investment banking practice as a Senior Managing Director.

On the ground for Bounces' first major trip: the 2025 Australian Open.

Optimism appears to be in short supply entering 2025, replaced largely by exhaustion. So what are the options for making 2025 over-deliver on expectations?...

Novo Nordisk received a lump of coal in its stocking this season. It arrived in the form of Phase III data for its most important weight loss candidate, Ca...

Novo Nordisk has received a lump of coal in its stocking this season. It arrived in the form of Phase III data for its most important weight loss candidate...

Robert “Bob” Temple, who helped revolutionize the ways medical products are developed and regulated, is retiring from FDA after 52 years at t...

Leading companies through the turbulence of the past few years and the uncertainty of the next ones takes not just resilience, but an ability to grapp...

The growing ability to learn from patient samples begets the responsibility to do so, according to Gentech’s SVP and Global Head of Translational Me...

The Investor Relations website contains information about uniqure BV's business for stockholders, potential investors, and financial analysts.

Tubulis is innovating on the linker, payload and drug-to-antibody ratio of antibody-drug conjugates, with a modular platform that optimizes for ADC stabili...

Giving Robert F. Kennedy Jr. control of HHS would be disastrous, argues Washington Editor Steve Usdin on the latest BioCentury This Week podcast. Expanding...

Positive vibes about biotech emanating from the Jefferies Healthcare Conference were overshadowed by the uncertainty that lies ahead as a result of the U.S...

Eli Lilly and Novo Nordisk have clearly set themselves apart from other pharmas in the scale of their pipelines, revenues and business development activiti...

Positive vibes about biotech emanating from the Jefferies Healthcare Conference were overshadowed by the uncertainty that lies ahead as a result of the U.S...

Biotechs are shedding their reliance on pharma to get drugs across the finish line for approval, with half the FDA approved drugs now being taken the whole...

There’s an unspoken rule that cancer drugs should be tested in the sickest patients first. It’s time to turn that paradigm on its head.&...

Great to be in London for London Life Sciences Week anchored by the Jefferies London Healthcare conference. Join us at the BioCentury Inc.-BioIndustry…

There’s an unspoken rule that cancer drugs should be tested in the sickest patients first. It’s time to turn that paradigm on its head.&...

As the amyloid field has settled the debate about efficacy that raged for two decades or more, it finds itself now needing to manage that efficacy against ...

New York Times reporters have trained a retrospectroscope onto Alzheimer’s disease trials and concluded that drug companies and academic researchers...

 The new political reality in Washington presents opportunities, threats and a lot of food for thought for leaders of industries like biopharma that n...

Our industry is rife with myths that shape its sectors’ perceptions of each other. The cost is that it slows down, impairs, or even prevents th...

It’s too soon to conclude anti-amyloid therapies are safe for use by Alzheimer’s patients in the real world, even as early reports are encour...

Alzheimer’s therapy Leqembi is being used according to its label and without a spike in adverse events over the rates observed in clinical trials, a...

Over the last two decades, scientific discoveries have propelled a surge in cancer drug development, but progress in bringing new medicines to patients has...

Former President Donald Trump’s embrace of Robert F. Kennedy Jr. has sparked concerns in the biopharma industry over the politicization of public he...